Supporting Research
This review tries to describe the physiological functions of progesterone and its receptors, genomic and non-genomic signaling, splice variants, and a different aspect of progesterone signaling. Furthermore, we seek to address or attempt to discuss the following pertinent questions on steroid hormone signaling; How does progesterone influence breast cancer progression? How does it change the molecular pathways in breast cancer with different receptor statuses, the specific role of each isoform, and how does the ER/and PR ratio affect progesterone signaling?
https://www.ahajournals.org/doi/10.1161/circ.127.suppl_12.AP039
https://holtorfmed.com/pdf/01-Bioidentical-hormone-debate.pdf
The following Abstract discusses BBHRT (Biomimetic Bioidentical Hormone Replacement Therapy) for breast cancer patients, and their effect on quality of life.
First developed by T. S. Wiley as the Wiley Protocol, Biomimetic Bio-identical HRT (BBHRT) has been in the public domain for over 17 years. Physiologic Restoration™ has its origins in BBHRT. The abstract refers to the use of BBHRT in Oncologist Dr. Julie Taguchi’s observational study of oncology and the subjective improvement of menopausal symptoms.
WHN Board Member, Dr. Julie Taguchi is currently the Principal Investigator of the new and critically important BHOT (Bioidentical Hormones on Trial) study for WHN. We will keep you posted on our progress with this key study, and will publish the results.
https://ascopubs.org/doi/abs/10.1200/JCO.2017.35.7_suppl.113
Bone density improvement can be significant for women on Rhythmic Hormone Restoration.
This is a patient screening that shows after 7 years on the protocol, ages 52-59, bone mineral density (BMD) in the hip increased from 0.998 g/cm2 (normal) to 1.109 g/cm2 in 7 years or a total 12.3% increase in 7 years.
BMD in the spine also increased 5.4% over 7 years, but started out as normal bone.
Note that BMD is different in different bones and that gain or loss of bone occurs at different rates as well.

